Study of XNW28012 in Subjects with Advanced Solid Tumors Who Failed Standard Treatments

This is an open-label, dose escalation, multicenter, phase 1, first-in-human study of XNW28012 in subjects with advanced solid tumors who have failed current standard anti-tumor therapies or are intolerant to such therapies. The study consists of two parts: a dose escalation part and a dose expansion part.

Trial Details

NCT ID
NCT06799637
Phase
PHASE1 / PHASE2
Sponsor
Evopoint Biosciences Inc.
Status
RECRUITING
Cancer Type
Ovarian Cancer
Interventions
  • XNW28012
Locations (sample)
  • Hefei, Anhui, China|31.86389,117.28083
  • Hefei, Anhui, China|31.86389,117.28083
  • Beijing, Beijing Municipality, China|39.9075,116.39723
  • Beijing, Beijing Municipality, China|39.9075,116.39723
  • Chongqing, Chongqing Municipality, China|29.56026,106.55771

Key Eligibility Criteria

  • For the dose escalation part: subjects with histologically or cytologically confirmed advanced and/or metastatic solid tumors who have failed the e…
  • For the dose expansion part: subjects must have a histological or cytological diagnosis of progressive, locally advanced, and/or metastatic ovarian…
  • Age ≥ 18 years old at the time of consent.
  • Subjects must have at least 1 measurable lesion as defined per RECIST version 1.1 (for dose expansion part only).

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Ovarian Cancer Trials on Trialify →